Abrégé

Chlorogenic acid is used in the preparation of a medicine for preventing or treating pain. The pain can be cancer pain, skeletal muscle pain and the like. A medicine for preventing or treating pain, the medicine being a pharmaceutical preparation prepared by using chlorogenic acid as an active ingredient and adding pharmaceutically acceptable auxiliary materials. Chlorogenic acid may effectively relieve cancer pain and bone joint pain, and may replace analgesic drugs such as opioids and non-steroidal anti-inflammatory drugs in treatment.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes

Abrégé

The use of chlorogenic acid in the preparation of a drug for treating diffuse midline gliomas, which use belongs to the field of medicine. Cell experiments and animal experiments prove that chlorogenic acid can induce the apoptosis of diffuse midline brain stem glioma cells, and the proportion of apoptotic cells increases as the chlorogenic acid concentration increases. Compared with temozolomide, a conventional standard chemotherapeutic drug for glioblastoma, chlorogenic acid has a significantly improved inhibitory effect on diffuse brain stem glioma, and has low toxicity and few side effects. Chlorogenic acid significantly prolongs the survival time of a mouse model of diffuse brain stem glioma. Chlorogenic acid has an inhibitory effect on diffuse brain stem glioma, can inhibit the growth of diffuse brain stem glioma, provides a new, safer option for treating diffuse midline gliomas, and has good application prospects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

Chlorogenic acid is used in the preparation of a medicine for treating a central nervous system tumor. It is discovered that chlorogenic acid may effectively treat diffuse large B-cell lymphoma, which provides a new clinical treatment of central nervous system tumors, especially diffuse large B-cell lymphoma.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

A pharmaceutical composition containing chlorogenic acid can be used in the preparation of a drug for treating the early Alzheimer's disease. In the pharmaceutical composition chlorogenic acid is used as a main active ingredient, and 3-coumaroylquinic acid is used as an auxiliary ingredient. The latter can effectively improve the therapeutic effect of chlorogenic acid for treating the early Alzheimer's disease.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

A pharmaceutical composition containing chlorogenic acid is used in the preparation of a medicament for treating pathologic jaundice. In the pharmaceutical composition, chlorogenic acid is used as a main active ingredient, and bifidobacteria and human milk oligosaccharides are used as auxiliary ingredients. The latter can effectively enhance the therapeutic effect of chlorogenic acid for treating pathologic jaundice, thereby reducing the amount thereof. The pharmaceutical composition can effectively reduce the contents of total bilirubin and indirect bilirubin in blood, and provides a new means and choice for pharmacotherapy of pathologic jaundice, especially hemolytic jaundice.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61K 35/745 - Bifidobactéries
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

A pharmaceutical composition for treating hyperlipidemia and a preparation method therefor are provided. The pharmaceutical composition contains chlorogenic acid, vitamins, pharmaceutically acceptable excipients and optional microelements. The pharmaceutical composition for treating hyperlipidemia reduce can serum total cholesterol and serum triglyceride, and increase the content of high-density lipoproteins.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/355 - Tocophérols, p. ex. vitamine E
• A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
• A61K 33/04 - Soufre, sélénium ou tellureLeurs composés
• A61K 33/24 - Métaux lourdsLeurs composés
• A61K 33/30 - ZincSes composés
• A61K 33/32 - ManganèseSes composés
• A61P 3/06 - Antihyperlipémiants

Abrégé

The present invention relates to the field of biomedicine, and provides the use of a pharmaceutical composition comprising chlorogenic acid in the preparation of a drug for treating the early Alzheimer's disease. In the pharmaceutical composition of the present invention, chlorogenic acid is used as a main active ingredient, and 3-coumaroylquinic acid is used as an auxiliary ingredient. The latter can effectively improve the therapeutic effect of chlorogenic acid for treating the early Alzheimer's disease. The research and development of the pharmaceutical composition of the present invention have very important significance on intervention from the early stage of the Alzheimer's disease, delay of the progress of the Alzheimer's disease, and improvement of the life quality of a patient.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present invention belongs to the field of medicines, and provides a use of chlorogenic acid in the preparation of a medicine for treating a central nervous system tumor. In the present invention, it is found for the first time that chlorogenic acid may effectively treat diffuse large B-cell lymphoma, which provides a new and highly safe option for the clinical treatment of central nervous system tumors, especially diffuse large B-cell lymphoma, and has good application prospects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

A pharmaceutical composition for treating hyperlipidemia and a preparation method therefor. The pharmaceutical composition comprises chlorogenic acid, vitamins, pharmaceutically acceptable excipients and optional microelements. The pharmaceutical composition for treating hyperlipidemia has excellent effects in terms of reducing serum total cholesterol and serum triglyceride, and increasing the content of high-density lipoproteins. In addition, the pharmaceutical composition has clear components, a simple composition, safety and no side effects, and thus can be widely used in the clinical treatment of hyperlipidemia.

Classes IPC  ?

• A61K 33/30 - ZincSes composés
• A61K 33/32 - ManganèseSes composés
• A61K 33/04 - Soufre, sélénium ou tellureLeurs composés
• A61K 33/24 - Métaux lourdsLeurs composés
• A61K 33/34 - CuivreSes composés
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
• A61K 31/355 - Tocophérols, p. ex. vitamine E
• A61K 31/4415 - Pyridoxine, c.-à-d. vitamine B6
• A61K 31/714 - Cobalamines, p. ex. cyanocobalamine, vitamine B12
• A61K 31/315 - Composés du zinc
• A61P 3/06 - Antihyperlipémiants

Abrégé

The present invention belongs to the field of biomedicine, and provides use of a pharmaceutical composition containing chlorogenic acid in the preparation of a medicament for treating pathologic jaundice. In the pharmaceutical composition of the present invention, chlorogenic acid is used as a main active ingredient, and bifidobacteria and human milk oligosaccharides are used as auxiliary ingredients. The latter can effectively enhance the therapeutic effect of chlorogenic acid for treating pathologic jaundice, thereby reducing the amount thereof. The pharmaceutical composition of the present invention can effectively reduce the contents of total bilirubin and indirect bilirubin in blood, and provides a new means and choice for pharmacotherapy of pathologic jaundice, especially hemolytic jaundice.

Classes IPC  ?

• A61K 35/745 - Bifidobactéries
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The present invention relates to the field of medicine, and provides a use of an injection composition containing chlorogenic acid and diammonium glycyrrhizinate in the preparation of an injection having a skin whitening effect. In the composition of the present invention, the chlorogenic acid is used as a main active ingredient, the diammonium glycyrrhizinate is used as an auxiliary ingredient, and the diammonium glycyrrhizinate can effectively enhance the skin whitening effect of the chlorogenic acid, so that the dosage of the chlorogenic acid is reduced. Pharmacodynamic experiments show that the composition containing chlorogenic acid and diammonium glycyrrhizinate of the present invention has a remarkable inhibition effect on synthesis of melanin, and the effect of the composition is obviously superior to that of single use of chlorogenic acid or tranexamic acid.

Classes IPC  ?

• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 17/16 - Émollients ou protecteurs, p. ex. contre les radiations
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate

Abrégé

Chlorogenic acid is used in the preparation of a drug for treating and/or preventing ocular inflammation. Chlorogenic acid can significantly alleviate symptoms of uveitis and scleritis, and has good treatment effects on ocular inflammation.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 27/02 - Agents ophtalmiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Chlorogenic acid is used in the preparation of a medicine for preventing or treating pain. The pain can be cancer pain, skeletal muscle pain and the like. A medicine for preventing or treating pain, the medicine being a pharmaceutical preparation prepared by using chlorogenic acid as an active ingredient and adding pharmaceutically acceptable auxiliary materials. Chlorogenic acid may effectively relieve cancer pain and bone joint pain, and may replace analgesic drugs such as opioids and non-steroidal anti-inflammatory drugs in treatment.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes

Abrégé

Disclosed is an injection for treating herpes zoster, comprising components of chlorogenic acid, a filling agent, and an antioxidant. The mass ratio of the chlorogenic acid, the filling agent, and the antioxidant is 30: 20-160: 0.5-4. The injection for treating the herpes zoster is an agent prepared by using an effective amount of chlorogenic acid as the active ingredient and adding pharmaceutically acceptable adjuvants or auxiliary ingredients, and can effectively treat the herpes zoster when administrated by injection, thereby providing a new and high-security option for clinical treatment of the herpes zoster, and achieving good application prospects.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès

Abrégé

Chlorogenic acid and/or coumaroylquinic acid are employed in preparation of drugs for treating squamous cell carcinoma. Chlorogenic acid or coumaroylquinic acid can effectively treat squamous cell carcinoma. A combination of chlorogenic acid and coumaroylquinic acid can also achieve effective treatment, can yield a synergistic effect, and has excellent application prospect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

Chlorogenic acid or compositions containing chlorogenic acid are used in preparation of a medicament for treating sarcoma. The chlorogenic acid composition includes chlorogenic acid and coumaroyl quinic acid, can effectively treat sarcoma, and has a better therapeutic effect than the chemotherapeutic medicament doxorubicin. The experimental results show that the combination of chlorogenic acid and coumaroylquinic acid can have a synergistic effect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
• A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 35/00 - Agents anticancéreux
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique

Abrégé

An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 35/00 - Agents anticancéreux
• A61K 9/51 - Nanocapsules
• A61K 31/225 - Acides polycarboxyliques
• A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
• A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/38 - CelluloseSes dérivés
• A61K 47/40 - CyclodextrinesLeurs dérivés

Abrégé

Chlorogenic are used in preparing a drug for preventing or blocking brain and/or bone metastases of lung cancer. The chlorogenic acid can effectively prevent or block metastasis of tumor cells of a patient with lung cancer, such as small cell lung cancer, squamous cell lung cancer, and lung adenocarcinoma.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

A drug for use in combination for treating high-grade brain tumors in response to ineffective standard treatment for postoperative recurrence. The drug for includes chlorogenic acid and temozolomide of the same or different unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. A pharmaceutical composition includes chlorogenic acid and temozolomide can be used to prepare a drug for treatment of high-grade brain tumors for which standard treatment for postoperative recurrence is ineffective.

Classes IPC  ?

• A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 35/00 - Agents anticancéreux

Abrégé

A drug combination for treatment of amyotrophic lateral sclerosis includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium, as well as pharmaceutically acceptable carriers, in which chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium are unit preparations having same or different specifications, that are simultaneously or separately administrated. The combination of chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, and creatine phosphate sodium shows a synergistic effect on amyotrophic lateral sclerosis, thus provides a combination with excellent therapeutic effect on amyotrophic lateral sclerosis, which delays the progression of amyotrophic lateral sclerosis.

Classes IPC  ?

• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/355 - Tocophérols, p. ex. vitamine E
• A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels

Abrégé

A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a chlorogenic acid self-emulsifying composition of a nano-scale drug delivery system, and a use thereof. The self-emulsifying composition of a nano-scale drug delivery system contains a complex formed by chlorogenic acid-lipid materials with a complexation rate of more than 70％, a specific oil phase, an emulsifier and a co-emulsifier, but does not contain an aqueous phase, which can be used for resisting tumors, anti-inflammatory immunity and antiviral treatment.

Classes IPC  ?

• A61K 9/107 - Émulsions
• A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 39/06 - Antiradicaux libres ou antioxydants
• A61P 31/04 - Agents antibactériens
• A61P 31/12 - Antiviraux
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61P 3/06 - Antihyperlipémiants
• A61P 9/12 - Antihypertenseurs
• A61P 37/02 - Immunomodulateurs
• A61P 35/00 - Agents anticancéreux

Abrégé

A drug that contains chlorogenic acid is effective in treating chordoma. When administered to a patient in need thereof, chlorogenic acid can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease.

Classes IPC  ?

• A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
• A61P 35/00 - Agents anticancéreux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées

Abrégé

A use of chlorogenic acid in the preparation of a medicine for preventing or treating pain, the pain comprises cancer pain, skeletal muscle pain and the like. A medicine for preventing or treating pain, the medicine being a pharmaceutical preparation prepared by using chlorogenic acid as an active ingredient and adding pharmaceutically acceptable auxiliary materials. Chlorogenic acid may effectively relieve cancer pain and bone joint pain, and may replace analgesic drugs such as opioids and non-steroidal anti-inflammatory drugs in treatment.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61K 9/08 - Solutions
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
• A61K 38/09 - Hormone libérant l'hormone lutéinisante [LHRH]Peptides apparentés
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides a 3-caffeoylquinic acid derivative, a preparation method therefor and use thereof. The 3-caffeoylquinic acid derivative is as shown in formula I. In addition, the 3-caffeoylquinic acid derivative also has the effects of antisepsis and anti-inflammation and antioxidation. The 3-caffeoylquinic acid derivative can be used for preparing anti-tumor and antiviral drugs, particularly drugs for treating the specific tumors and viruses, and can also be used for preparing antibacterial, anti-inflammatory and antioxidant drugs.

Classes IPC  ?

• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés
• C07C 67/48 - SéparationPurificationStabilisationEmploi d'additifs
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 31/12 - Antiviraux
• A61P 35/00 - Agents anticancéreux

Abrégé

Use of a chlorogenic acid derivative as a reference substance in detection of the quality of preparations comprising chlorogenic acid and mannitol.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• G01N 30/36 - Contrôle des paramètres physiques du fluide vecteur dans les systèmes liquides à haute pression

Abrégé

A pharmaceutical composition for treating amyotrophic lateral sclerosis, a preparation method therefor and use thereof. The pharmaceutical composition consists of chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, sodium creatine phosphate, and a pharmaceutically acceptable carrier. The chlorogenic acid, vitamin E, vitamin C, coenzyme Q10 and sodium creatine phosphate are unit dosage formulations of the same or different specifications for simultaneous or separate administration.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/355 - Tocophérols, p. ex. vitamine E
• A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
• A61K 31/122 - Cétones ayant l'atome d'oxygène lié directement à un cycle, p. ex. quinones, vitamine K1, anthraline
• A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

Disclosed is a pharmaceutical composition and a use thereof in a drug preparation for treating kidney cancer, belonging to the field of biomedicine. The pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61P 35/00 - Agents anticancéreux

Abrégé

Application of chlorogenic acid and/or coumaroyl guinic acid in preparation of drugs for treating squamous cell carcinoma. Chlorogenic acid or coumaroyl guinic acid can effectively treat squamous cell carcinoma; a combination of chlorogenic acid and coumaroyl guinic acid can also achieve effective treatment, can yield a synergistic effect, and has excellent application prospect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

A drug for use in combination for treating high-grade brain tumors in response to ineffective standard treatment for postoperative recurrence. The drug for use in combination comprises chlorogenic acid and temozolomide of the same or different unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. Provided are a pharmaceutical composition comprising chlorogenic acid and temozolomide, a method for preparing the same, and a use of the drug for use in combination and the pharmaceutical composition for preparing a drug for treatment of high-grade brain tumors for which standard treatment for postoperative recurrence is ineffective.

Classes IPC  ?

• A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed in the present invention is the use of chlorogenic acid in preparation of a medicament for treating sarcoma. The present invention further provides a chlorogenic acid combination and the use thereof in preparation of a medicament for treating sarcoma. The chlorogenic acid of the present invention can effectively treat sarcoma, and the therapeutic effect is superior to that of the chemotherapeutic medicament doxorubicin when being administered systematically or topically. The chlorogenic acid composition of the present invention comprises chlorogenic acid and coumaroyl quinic acid, can effectively treat sarcoma, and has a better therapeutic effect than the chemotherapeutic medicament doxorubicin. The experimental results of the present invention show that the combination of chlorogenic acid and coumaroylquinic acid can have a synergistic effect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides a use of chlorogenic acid in preparing a drug for preventing or blocking brain and/or bone metastases of lung cancer. The chlorogenic acid of the present invention can effectively prevent or block metastasis of tumor cells of a patient with lung cancer, such as small cell lung cancer, squamous cell lung cancer, and lung adenocarcinoma, in the body, thereby improving the quality of life of the patient while effectively prolonging the patient's life. The present invention has good prospects for clinical application.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

The present invention relates to the field of biomedicine and disclosed thereby are a pharmaceutical composition and a use thereof in preparing a drug for treating tumor multi-drug resistance; the pharmaceutical composition comprises chlorogenic acid and coumaroylquinic acid, and may be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid may exert a synergistic effect; the present invention has a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides use of chlorogenic acid in preparation of a drug for treating chordoma. The chlorogenic acid of the present invention can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease, having good clinical application prospect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux
• A61K 9/08 - Solutions
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées

Abrégé

Provided are a use of chlorogenic acid in preparing pharmaceuticals for the inhibition of LAG-3 and a use of chlorogenic acid in preparing pharmaceuticals for the treatment of LAG-3-mediated diseases. The inhibition of LAG-3 by chlorogenic acid is useful in cancer therapy, anti-viral therapy, and sepsis treatment. The oral bioavailability of chlorogenic acid is enhanced by preparing chlorogenic acid as a gastric floating tablet.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 31/04 - Agents antibactériens
• A61P 35/00 - Agents anticancéreux
• A61K 9/16 - AgglomérésGranulésMicrobilles
• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés

Abrégé

The present invention provides a combined drug for treating tumors. The combined drug comprises chlorogenic acid and anti-CTLA-4 monoclonal antibodies in preparations having same or different specifications and units, which are administered at the same time or separately, and comprises a pharmaceutically acceptable carrier. In the present invention, the combined use of the chlorogenic acid and the anti-CTLA-4 monoclonal antibodies can generate a synergistic effect, can effectively reduce toxic and side effects of the anti-CTLA-4 antibodies, can alleviate damages of organisms caused after only the anti-CTLA-4 antibodies is used, and has good clinical application prospects.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

A combined drug for treating diseases related to a tumor necrosis factor family. The combined drug comprises chlorogenic acid and drugs for treating diseases related to the tumor necrosis factor family, which have same or different specifications and units and administered at the same time or separately, and comprises a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and the drugs for treating diseases related to the tumor necrosis factor family can produce a synergistic effect in the treatment of the diseases related to the tumor necrosis factor family, can improve the therapeutic effect when only TNF-α inhibitor is used, can reduce inflammatory infiltration in articular cavities and the erosion degree of articular cartilages of a rheumatoid arthritis patient, can enhance the therapeutic effect of urelumab for inhibiting tumor progression, can improve the inhibition rate of TARIL for tumor cells, the combined drug prepared by using chlorogenic acid and tumor necrosis factor family-related drugs can produce remarkable synergistic effect, has a good therapeutic effect and low toxicity, and has good clinical application prospects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 38/19 - CytokinesLymphokinesInterférons
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux

Abrégé

A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effect of synergistic interaction, which thus overcomes the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome, and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
• A61K 38/09 - Hormone libérant l'hormone lutéinisante [LHRH]Peptides apparentés
• A61P 35/00 - Agents anticancéreux

Abrégé

An antitumor combination drug and a use thereof in the preparation of an anticancer drug. The antitumor combination drug comprises chlorogenic acid, an antitumor drug, and a pharmaceutically acceptable adjuvant. Also disclosed is a use of chlorogenic acid for the preparation of a toxicity and side effect inhibitor for an anticancer drug, the anticancer drug being a drug targeting EGFR. The antitumor combination drug can enhance targeting efficacy of EGFR-targeting drugs in non-small cell carcinoma, breast cancer, malignant glioma, and nasopharyngeal carcinoma, reduce toxicity and side effects of the EGFR-targeting drugs, and reverse drug tolerance to the EGFR-targeting drugs.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

The present invention provides a use of chlorogenic acid in the preparation of a drug for treating and/or preventing ocular inflammation. Chlorogenic acid can significantly alleviate symptoms of uveitis and scleritis, and has good treatment effects on ocular inflammation.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 27/02 - Agents ophtalmiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsÉmulsions
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat

Abrégé

Use of chlorogenic acid in preparation of drugs or health-care products for stimulating appetite. A pharmacological experiment indicates that chlorogenic acid can significantly increase the food intake of an anorexia rat, and the weight thereof. The effect of the chlorogenic acid is equivalent to that of a commercially available drug, i.e., Jiangzhong indigestion tablets, which proves that the chlorogenic acid has a prominent effect of stimulating appetite, can be used for treatment of anorexia, and has a wide clinical application prospect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 37/04 - Immunostimulants
• A61P 1/14 - Eupeptiques, p. ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs

Abrégé

Provided is the use of a compound represented by formula I, a stereoisomer, or a pharmaceutically acceptable salt, or a solvate, or a crystalline form, or an isotopologue thereof in preparation of a sensitizer for a tumour immunotherapeutic drug, wherein R1 to R3 are independently selected from a hydroxyl, C1-C6 alkoxy, a substituent represented by formula II or a cis isomer thereof; R4, and R5 are independently selected from a hydrogen, halogen, C1-C6 alkyl, hydroxy or C1-C6 alkoxy. The chlorogenic acid and the derivatives thereof of the present invention can be used as sensitizers for tumour immunotherapeutic drugs to make the therapeutic drugs better play the role of killing tumour cells, when used in combination with tumour immunotherapeutic drugs.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides an application of chlorogenic acid in preparing medicines for treating lupus erythematosus. The chlorogenic acid can improve an immunity function. The present invention provides a preparation for treating lupus erythematosus, comprising chlorogenic acid and pharmaceutically acceptable auxiliary materials. The present invention further provides a combined medicine comprising chlorogenic acid and medicines for treating lupus erythematosus.

Classes IPC  ?

• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The present invention provides one method for the preparation of pharmaceutically acceptable chlorogenic acid, which comprises the following steps: a. Treating the sample aqueous solution; b. Freezing; c. Thawing and filtering; d. Treating the residue organic phase; e. Concentrating and crystallizing; f. Choosing the number of times to repeat steps a-e according to the variability of chlorogenic acid content in samples; g. Drying. If the chlorogenic acid extract is isolated and purified using this method, water-soluble impurities and liposoluble impurities can be well removed, that allows the impurity content of final products has fulfilled the requirements for medicine; meanwhile, the procedures of this method are simple, and organic solvents can be recycled for further use, with low cost. This method can be applied for the further isolation and purification of chlorogenic acid extract obtained by various ways, especially for the preparation of pharmaceutically acceptable chlorogenic acid.

Classes IPC  ?

• B01D 9/00 - Cristallisation
• B01D 9/04 - Cristallisation à partir de solutions en concentrant les solutions par extraction du solvant congelé
• C07C 35/14 - Composés comportant au moins un groupe hydroxyle ou O-métal lié à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons monocycliques contenant des cycles à six chaînons avec plusieurs groupes hydroxyle liés au cycle
• C07C 39/10 - PolyhydroxybenzènesLeurs dérivés alkylés
• C07C 67/48 - SéparationPurificationStabilisationEmploi d'additifs
• C07C 67/52 - SéparationPurificationStabilisationEmploi d'additifs par modification de l'état physique, p. ex. par cristallisation
• C07C 67/56 - SéparationPurificationStabilisationEmploi d'additifs par traitement solide-liquideSéparationPurificationStabilisationEmploi d'additifs par absorption-adsorption chimique
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés

Abrégé

1, cell parameters are as follows: a=7.7291(2)Å, b=10.9808(2)Å, c=36.5334(7)Å, α=β=γ=90.00°, Z=8, and a cell volume is 3100.65(11)Å3. The content of the chlorogenic acid crystal form in the preparation is 10-5000 mg/g. The preparation is advantageous to bioavailability, and can be used for preparing medicines for treating tumor, psoriasis and other immune system diseases, resisting oxidation, protecting liver and gallbladder, treating cardiovascular diseases, and resisting viruses.

Classes IPC  ?

• A61K 31/235 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
• C07C 69/76 - Esters d'acides carboxyliques dont un groupe carboxyle estérifié est lié à un atome de carbone d'un cycle aromatique à six chaînons
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 47/02 - Composés inorganiques
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine

Abrégé

The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of oligodendroglioma. Chlorogenic acid according to the present invention has an inhibitory action against oligodendroglioma, and can inhibit the growth of brain tumor stem cells, thus can partly substitute chemoradiation. Chlorogenic acid can alleviate the unwell response of patients caused by chemoradiation, and become a new medicinal therapeutic means and choose for treatment of oligodendroglioma.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of psoriasis. Chlorogenic acid, a small molecular compound, is a biological response modifier focusing on the overall regulation, and has a good effect on rebuilding the homeostasis of immune function. Harmful action of chlorogenic acid on liver and kidney is not found, and it can be long-term used, without toxic and side effects on body. Chlorogenic acid is safe and effective, with low recurrence rate, and it can improve life quality of patients. It has an obvious effect on psoriasis, especially on psoriasisvulgaris and psoriasis pustulosa, thus for treatment of psoriasis, chlorogenic acid has a wide application prospects.

Classes IPC  ?

• A61K 31/235 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

3. Also provided is a preparation method for the crystalline form. The present crystalline form has good stability and does not significantly change during storage for 48 months in a cool, dark place, and the various indices all meet the relevant requirements for active pharmaceutical ingredients. The crystallization process provided by the present invention can not only use raw materials having different purities to prepare the same crystalline form of chlorogenic acid, but can also significantly reduce solvent residue in the raw materials, thereby improving product safety.

Classes IPC  ?

• C07C 67/52 - SéparationPurificationStabilisationEmploi d'additifs par modification de l'état physique, p. ex. par cristallisation
• C07C 69/618 - Esters d'acides carboxyliques avec un groupe carboxyle lié à un atome de carbone acyclique et comportant un cycle aromatique à six chaînons dans la partie acide avec insaturation autre que celle du cycle aromatique à six chaînons
• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés

Abrégé

The present invention provides use of chlorogenic acid in preparation of a medicine for treating progeria. Chlorogenic acid can effectively treat progeria. Compared with a positive medicine namely rapamycin, the chlorogenic acid has a superior treatment effect and a smaller side effect.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 5/00 - Médicaments pour le traitement des troubles du système endocrinien

Abrégé

The present invention provides use of chlorogenic acid in preparing a drug for treating amyotrophic lateral sclerosis. The chlorogenic acid is beneficial to alleviating disease symptoms of amyotrophic lateral sclerosis (ALS), beneficial to biologically synthesizing neurotrophic factors and beneficial to repairing and protecting neurons.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie

Abrégé

The present invention provides for a use of chlorogenic acid in preparing a drug for treating urticaria. The chlorogenic acid can alleviate the symptom of increased permeability of blood capillaries caused by the urticaria, can inhibit degranulation and histamine release of mast cells, and is beneficial to alleviating the symptoms of non-immunologic urticaria.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 37/08 - Agents antiallergiques

Abrégé

Provided is an application of chlorogenic acid in a preparing a drug for treating a yolk sac tumor. The chlorogenic acid can effectively treat a yolk sac tumor, and at a high dosage has a similar effect to the chemotherapeutic drug cyclophosphamide but with reduced side effects, and therefore can replace traditional chemotherapeutic drugs.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

Provided is a use of a chlorogenic acid in the preparation of drugs for treating bone sclerosis. The chlorogenic acid effectively treats the bone sclerosis, and exhibits a better treatment effect than a positive control group combining positive drugs such as prednisone with tendon-relaxing and circulation-stimulating tablets, with less side effects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget

Abrégé

Disclosed are a eucommia leaf extract, and preparation method and use thereof. The extract is a liquid of the eucommia leaf or an ethyl alcohol extract, and has chlorogenic acid of a content not less than 9%, geniposidic acid of a content not less than 1% and aucubin of a content not less than 1%. The extract has a good effect on psoriasis.

Classes IPC  ?

• A61K 36/46 - Eucommiaceae (famille de l'eucomia), p. ex. gutta percha
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 31/075 - Éthers ou acétals
• A61K 9/08 - Solutions
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61P 17/06 - Antipsoriasiques
• A61K 127/00 - Parties de plantes contenant des feuilles ou obtenues à partir de feuilles

Abrégé

The present invention provides a chlorogenic acid powder-injection. The chlorogenic acid powder-injection is prepared from the following raw materials in parts by weight: 1-120 parts of chlorogenic acid, 1-320 parts of a bracket agent and 1-8 parts of an antioxidant. The present invention further provides a preparation method of the powder-injection. The chlorogenic acid powder-injection provided in the present invention is good in stability, strong in re-solubility and safe in clinical use.

Classes IPC  ?

• A61K 31/235 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle
• A61K 31/25 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques avec des alcools polyoxyalkylés, p. ex. esters de polyéthylèneglycol
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine

Abrégé

Eucommia leaves. After inclusion by the inclusion technology, the liquid drugs become powder, and thus easily oxidized natural products could be protected. Moreover, the damage for active ingredients caused by air can be prevented, and the stability and the taste may get improved.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 36/46 - Eucommiaceae (famille de l'eucomia), p. ex. gutta percha
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 36/074 - Ganoderma

Abrégé

Provides are uses of chlorogenic acid in the preparation of medicines for treating vitiligo. Experiments show that chlorogenic acid can alleviate pathological changes of a vitiligo model, reduce expression of TNF- and IL-4 in damaged skin, promote generation of melanocytes, and provide a theoretical basis for treating vitiligo in clinic by using chlorogenic acid.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques

Abrégé

The present invention provides a preparation method for medicinal chlorogenic acid. The method comprises the following steps: a, carrying out aqueous phase treatment on a sample; b, freezing; c, thawing and filtering; d, carrying out organic phase treatment on the filter residue; e, concentrating and crystallizing; f, selecting the repeating times of steps a-e according to the difference of the contents of chlorogenic acid in the sample; and g, drying. A chlorogenic acid extract is separated and purified by the method, water-soluble impurities and fat-soluble impurities in the extract can be desirably removed, and thus the impurity content of the final product meets the medicinal requirements. Besides, the method has simple operation, recyclable organic solvent and low cost, is suitable for further separation and purification of a chlorogenic acid extract extracted by all kinds of methods, and is especially suitable for the preparation of medicinal chlorogenic acid.

Classes IPC  ?

• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés
• C07C 67/48 - SéparationPurificationStabilisationEmploi d'additifs
• C07C 67/52 - SéparationPurificationStabilisationEmploi d'additifs par modification de l'état physique, p. ex. par cristallisation

Abrégé

The present invention provides a device for enriching and purifying compounds. The present invention also provides a use method for the device and a purification method for chlorogenic acid. According to the present invention, extracted clear liquor or concentrated clear liquor of high and low-concentration chlorogenic acid is effectively enriched in an enrichment form of combining a single column with tandem columns, so that the dynamic adsorption capacity of resin per unit volume is increased, the problem of non-continuous sample loading adsorption of the single column due to dynamic adsorption leakage is solved, and the problem of reduced chlorogenic acid adsorption amount of the resin due to additional impurity adsorption caused by continuous penetration sample loading of the tandem columns is also solved; meanwhile, a mode of selective elution by the single column is adopted, so that the content of impurities in elution liquid is reduced, the product purity is improved, and the problem of reduced product purity due to continuous release of the impurities to the elution liquid by the resin during tandem elution is solved.

Classes IPC  ?

• B01D 15/10 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement
• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés
• C07C 67/56 - SéparationPurificationStabilisationEmploi d'additifs par traitement solide-liquideSéparationPurificationStabilisationEmploi d'additifs par absorption-adsorption chimique

Abrégé

The present invention provides a use of chlorogenic acid in manufacturing medicaments for treating oligodendroglioma. The chlorogenic acid can inhibit oligodendroglioma and the growth of brain tumor stem cells, partially substitute radiotherapy and chemotherapy, and relieve the uncomfortable response of a patient caused by radiotherapy and chemotherapy.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

A use of chlorogenic acid in the preparation of a drug treating psoriasis. Chlorogenic acid is a small molecule compound and a biological response modifier, the focus being on overall modification, has a good effect with regard to rebuilding an immune function homeostatic state, has no damaging effects on the liver and kidneys, may be used long-term, does not produce toxic side effects on the body, is safe and effective, has a low recurrence rate, improves the quality of life of a patient, and has significant efficacy with regard to psoriasis, the effect being particularly evident with regard to psoriasis vulgaris and pustular psoriasis. Therefore, the treatment of psoriasis with chlorogenic acid has broad application prospects.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 17/06 - Antipsoriasiques

Abrégé

A chlorogenic acid lyophilised powder for injection and a preparation method therefor. The chlorogenic acid lyophilised powder for injection is prepared from raw materials having the following weight ratio: 30 parts chlorogenic acid, 60-90 parts mannitol and 1-3 parts sodium bisulphite. The crystalline form of the chlorogenic acid is an orthorhombic crystal system, the space group is P212121, the cell parameters are a = 7.7291 (2) Å, b = 10.9808 (2) Å and c = 36.5334 (7) Å, α = β = γ = 90°, Z = 8, and the cell volume is 3100.65 (11) Å3.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/02 - Composés inorganiques

Abrégé

Disclosed is use of chlorogenic acid in preparing drugs for treating ependymoma. As chlorogenic acid has the effect of inhibiting ependymoma, and can inhibit the growth of brain tumour stem cells, it can replace part of chemoradiotherapy, and reduce the uncomfortable reactions of patients caused by chemoradiotherapy. It is a new drug treatment means and choice for treating ependymoma.

Classes IPC  ?

• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided is a method for extracting chlorogenic acid from Eucommia leaves, comprising the following steps: a, weighing of Eucommia leaves; b, water extraction; c, pre-treatment; d, filtration; e, loading on a macroporous adsorbent resin; f, concentrating; g, drying: spray drying, an air inlet temperature being 150oC - 200oC, and an air outlet temperature being 50oC - 90oC, thereby obtaining a chlorogenic acid crude product. The present invention uses water extraction, pre-treatment, loading on a macroporous adsorbent resin column, concentrating and drying to prepare the chlorogenic acid crude product. A water extract liquid is not concentrated, and is directly loaded on the macroporous adsorbent resin for purification treatment after being pre-treated, thereby solving the problem of decomposition caused by chlorogenic acid being concentrated in water for a long time and heated unstably, at the same time as omitting a concentrating process link to shorten the production cycle. In addition, a crude product having 20-60% of various specifications may be produced by controlling concentration parameters of different eluents.

Classes IPC  ?

• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés
• C07C 67/56 - SéparationPurificationStabilisationEmploi d'additifs par traitement solide-liquideSéparationPurificationStabilisationEmploi d'additifs par absorption-adsorption chimique

Abrégé

Provided is a chlorogenic acid raw material or active pharmaceutical ingredient, containing chlorogenic acid having a weight percentage content of more than 98% and impurities having a weight percentage content of less than 1.9%. The impurities contain 3-coumaroylquinic acid, accounting for 0.1-0.5% of the total weight of the raw material or active pharmaceutical ingredient. Also provided is a preparation method for the chlorogenic acid raw material or active pharmaceutical ingredient, and a quality testing method. In the preparation method for the chlorogenic acid raw material or active pharmaceutical ingredient, after crystallisation, it is not necessary to undergo re-crystallisation process treatment, thereby reducing chlorogenic acid loss caused by re-crystallisation, and increasing product yield. At the same time, reduction of a re-crystallisation process shortens the production cycle, and applicability is strong, facilitating large-scale preparation of chlorogenic acid. Product quality controllability is strong, relevant impurities are all within a controlled range, and a relevant impurity having a content of more than 0.1% can be qualitatively and quantitatively analysed. The testing method has a high testing sensitivity for chlorogenic acid and analogues thereof. A mobile phase does not significantly interfere with related substance testing, the number of plates is high, the degree of separation is good, and peak symmetry is good.

Classes IPC  ?

• C07C 69/73 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés
• C07C 67/48 - SéparationPurificationStabilisationEmploi d'additifs
• C07C 67/52 - SéparationPurificationStabilisationEmploi d'additifs par modification de l'état physique, p. ex. par cristallisation

Abrégé

Provided is a crystalline form of chlorogenic acid. The crystalline form is an orthorhombic crystal system, the space group is P212121, the cell parameters are a=7.7291 (2) Å, b=10.9808 (2) Å, and c= 36.5334 (7) Å, α=β=γ=90.00°, Z=8, and the cell volume is 3100.65 (11) Å3. Also provided is a preparation method for the crystalline form. The present crystalline form has good stability and does not significantly change during storage for 48 months in a cool, dark place, and the various indices all meet the relevant requirements for active pharmaceutical ingredients. The crystallisation process provided by the present invention can not only use raw materials having different purities to prepare the same crystalline form of chlorogenic acid, but can also significantly reduce solvent residue in the raw materials, thereby improving product safety.

Classes IPC  ?

• C07C 67/52 - SéparationPurificationStabilisationEmploi d'additifs par modification de l'état physique, p. ex. par cristallisation
• C07C 69/732 - Esters d'acides carboxyliques dont le groupe carboxyle estérifié est lié à un atome de carbone acyclique et dont l'un des groupes OH, O-métal, —CHO, céto, éther, acyloxy, des groupes , des groupes ou des groupes se trouve dans la partie acide d'acides non saturés d'acides hydroxycarboxyliques non saturés

Abrégé

The present invention provides a chlorogenic acid powder-injection. The chlorogenic acid powder-injection is prepared from the following raw materials in parts by weight: 1-120 parts of chlorogenic acid, 1-320 parts of a bracket agent and 1-8 parts of an antioxidant. The present invention further provides a preparation method of the powder-injection. The chlorogenic acid powder-injection provided in the present invention is good in stability, strong in re-solubility and safe in clinical use.

Classes IPC  ?

• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 47/02 - Composés inorganiques
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire

Abrégé

A pharmaceutical composition is a preparation prepared by the raw materials in parts by weight: 1-300 parts of chlorogenic acid and 1-50 parts of Ganoderma lucidum spores oil. And a preparation method of the pharmaceutical composition. Chlorogenic acid can be used compatibly with Ganoderma lucidum spores oil, and synergistic effect is provided. Inclusion technique is applied to product development to achieve stability of oily liquid material Ganoderma lucidum spores oil and soild material eucommia leaves extract chlorogenic acid. Inclusion by the inclusion technique can make the liquid drugs powder, protect natural products easily oxidized, prevent air from damaging the active ingredient, improve stability and improve taste.

Classes IPC  ?

• A61K 36/074 - Ganoderma
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61K 9/08 - Solutions
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/46 - Pilules, pastilles ou comprimés effervescents
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61P 37/02 - Immunomodulateurs